Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice
October 3rd, 2010
This protocol describes the isolation and dissociation of mouse medulloblastoma tissue, and subsequent allografting of the tumor cells into immunocompromised recipient mice in order to initiate secondary medulloblastoma.
The overall goal of this procedure is to author topically allograft medulloblastoma tumor cells into an immunocompromised host to initiate a secondary tumor. This is accomplished by first associating primary medulloblastoma tissue into single cells and small cellular aggregates. The second step of the procedure is to prepare immunocompromised mice for intracranial injection.
The third step of the procedure is performing microinjection of tumor cells into the host cerebellum. The final steps of the procedure are maintaining and observing the tumor cell grafted hosts. Ultimately, results can be obtained that show secondary medulloblastoma formation in the hosts by the displayed neurological symptoms and histological analysis.
This technique can help answer key questions in cancer biology, such as determining the cellular origin of a tumor and factors important for initiating and propagating tumors, Microdisect and dissociate tumor tissue from m sparing medulloblastoma as described in the companion video article, isolation, enrichment and maintenance of medulloblastoma cell lines dilute the tumor cell suspension in neuro stem cell medium, so that four microliters of solution contains the appropriate number of dissociated tumor cells. Here, five times 10 to the six cells. Keep the dilute cell suspension in a 200 microliter micro centrifuge tube on ice.
Use a hair clipper to shave the dorsal posterior head region of an anesthetized immunocompromised host mouse revealing the posterior skull. Apply Betadine solution to the exposed scalp, followed by wiping with an alcohol pad. Repeat these two sterilizing steps twice.
Use a sterile scalpel to make a one-quarter inch incision in the posterior scalp. Use a sterile dental drill to drill a 0.5 millimeter bur hole, two millimeters to the right and two millimeters posterior to lambda. Hook the host mouses in sizes onto a stereotactic frame.
To secure the mouse load a bevel Tip 10 microliter syringe. With four microliters of tumor cell suspension, secure the syringe to a micro manipulator on the frame. Under the microscope, carefully descend and position the needle tip into the bur hole.
When the bevel of the syringe is below the skull surface, descend for three millimeters. Then back up the 0.5 millimeters to create a space in between the tip of the needle and the cerebellar tissue. Slowly with steady force over the course, 30 seconds, inject four microliters of the tumor cell suspension into the cerebellum of the host mouse.
Leave the needle in place for two minutes. Remove the needle and the syringe. Use a sterile auto clip to seal the wound.
Allow the mouse to recover on a warming blanket. After surgery, place the mouse back in a sterile housing cage and monitor behavior and for infection at the injection site. Seven days after surgery, remove the auto clip.
Mice will display typical medulloblastoma symptoms, symptoms between two and six months. Here is a typical example of secondary medulloblastoma tissue developed 26 days after injection of five times 10 to the five primary tumor cells. Hemat toin staining reveals the typical cellular morphology of medulloblastoma, including high nuclear to cytoplasmic ratio and nuclear polymorphism.
These secondary tumor cells are highly proliferative, as indicated by KI 67 expression, and they also robustly express membranous smoothened M two YFP. Using the companion protocol for primary mouse modelo blasts, stoma cells. These secondary modelo blasts stoma cells can be cultured and expanded for multiple passages.
Red arrows point to some red blood cells. Here is the same Representative tumor colony cultured at four days and at 14 days. The cultured tumor cells are bipolar, elongated with scan cytoplasm, and often radiate from a dense core of cellular aggregates.
While attempting these procedures, it's important to create a proper space in between the cere tissue and the tip of injection needle by sending it 0.5 millimeters after lowering it three millimeters beneath the skull surface.
View the full transcript and gain access to thousands of scientific videos
Overview
This protocol describes the isolation and dissociation of mouse medulloblastoma tissue, followed by the allografting of tumor cells into immunocompromised recipient mice to initiate secondary medulloblastoma. The procedure aims to study tumor formation and its effects on the host.
Key Study Components
Area of Science
- Neuroscience
- Oncology
- Translational Research
Background
- Medulloblastoma is a common pediatric brain tumor.
- Understanding tumor behavior in vivo is crucial for developing therapies.
- Immunocompromised mice provide a suitable model for studying tumor grafts.
- Histological analysis helps in assessing tumor formation.
Purpose of Study
- To isolate and dissociate medulloblastoma tissue for research.
- To initiate secondary tumors in a controlled environment.
- To observe neurological symptoms and tumor progression in hosts.
Methods Used
- Isolation of primary medulloblastoma tissue into single cells.
- Preparation of immunocompromised mice for tumor cell injection.
- Microinjection of tumor cells into the cerebellum of host mice.
- Monitoring and maintaining the health of grafted hosts.
Main Results
- Successful initiation of secondary medulloblastoma in host mice.
- Observation of neurological symptoms indicative of tumor growth.
- Histological analysis confirming tumor presence and characteristics.
- Insights into tumor behavior and host interactions.
Conclusions
- The protocol effectively models secondary medulloblastoma in mice.
- Results contribute to understanding tumor dynamics in vivo.
- Potential implications for developing targeted therapies.
Frequently Asked Questions
Executive Industry Relevance
Intracranial orthotopic allografting of medulloblastoma cells in immunocompromised mice enables rigorous investigation of tumor-initiating cell populations and their capacity to drive secondary tumor formation. This model supports mechanistic de-risking and target validation for pediatric brain tumor research, providing a translational bridge between cellular hypotheses and in vivo tumor biology. The approach is strategically positioned to inform early discovery and preclinical prioritization in oncology pipelines.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of the cellular origin and tumor-initiating potential of medulloblastoma subtypes.
- Supports functional validation of candidate cell populations implicated in tumor propagation.
- Facilitates mechanistic de-risking by linking in vitro findings to in vivo tumorigenicity.
- Provides a platform for evaluating the impact of genetic or molecular perturbations on tumor initiation.
Screening & Assay Development
- Establishes validated in vivo models for downstream efficacy and mechanistic studies.
- Enables reproducible assessment of tumor growth and histological features in a controlled setting.
- Supports quantitative evaluation of neurological symptoms and tumor burden as assay endpoints.
- Prepares a foundation for screening candidate interventions targeting tumor-initiating cells.
Translational & Preclinical Research
- Aligns with disease-relevant modeling of medulloblastoma subtypes observed in patients.
- Enables continuity from cellular discovery to preclinical validation of therapeutic hypotheses.
- Supports risk-adjusted advancement of candidate targets based on in vivo tumorigenicity data.
- Facilitates identification of translational biomarkers linked to tumor initiation and progression.
Pipeline & Workflow Integration
This intracranial allografting protocol integrates into the discovery-to-preclinical continuum by enabling direct testing of tumor-initiating hypotheses in vivo. It bridges early mechanistic studies with preclinical model validation, supporting informed go/no-go decisions for target advancement.
- Discovery Biology: Provides a robust platform for testing the null hypothesis regarding cell-of-origin and tumorigenic capacity.
- Screening: Delivers reproducible, quantitative outputs such as tumor incidence, growth kinetics, and histological markers.
- Analytics: Enables statistical comparison of tumor formation rates and phenotypic features across experimental groups.
- Translational Research: Models clinically relevant tumor subtypes and supports biomarker discovery aligned with patient disease.
- Enterprise Reuse: Offers a reusable in vivo system for iterative hypothesis testing and cross-program validation.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in target validation and reduces ambiguity in tumor biology.
- Operational Value: Standardizes in vivo tumor initiation assays for reproducibility and scalability.
- Strategic Value: Informs portfolio triage and capital allocation by providing early in vivo evidence of target relevance.
- Portfolio Impact: Supports risk-adjusted prioritization of discovery and preclinical assets based on functional tumorigenicity data.
Implementation Considerations
- Requires expertise in stereotactic surgery and animal model handling.
- Demands access to immunocompromised mouse colonies and histological analysis infrastructure.
- Necessitates rigorous cross-team standardization of injection coordinates and cell preparation.
- May require adaptation for different medulloblastoma subtypes or genetic backgrounds.
- Practical limitations include surgical precision and monitoring for post-procedural complications.
